Oct 28 (Reuters) - Transition Therapeutics Inc TTH.TO :
* Announces presentation of ELND005 phase 2/3 clinical study results at
clinical trials in alzheimer's disease (ctad) conference
* Co's unit TTIL, seeking guidance from regulators on design of phase 3 clinical studies for ELND005 program
* Source text for Eikon ID:nPn1T9xHN
* Further company coverage TTH.TO